You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

IL-2

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma Stage III, Melanoma Stage IV, Inoperable Disease Trial in Tampa (Interleukin-2, Ipilimumab, Nivolumab)

Recruiting
  • Melanoma Stage III
  • +2 more
  • Tampa, Florida
    Moffitt Cancer Center
Dec 6, 2022

Renal Cell Carcinoma Trial in Portland (High Dose IL-2, SBRT)

Active, not recruiting
  • Renal Cell Carcinoma
  • High Dose IL-2
  • SBRT
  • Portland, Oregon
    Portland Providence Medical Center
Jan 31, 2022

Leiomyosarcoma Trial in Bad Saarow, Berlin (Dinutuximab Beta, Zoledronic acid, Interleukin-2)

Recruiting
  • Leiomyosarcoma
  • Dinutuximab Beta, Zoledronic acid, Interleukin-2
  • Bad Saarow, Germany
  • +1 more
Jun 2, 2022

GVHD Trial in Hackensack (Cyclophosphamide and Sirolimus, Low dose IL-2 with Cytoxan + Sirolimus, Low dose IL-2, low dose

Terminated
Has Results
  • Graft Versus Host Disease
  • Cyclophosphamide and Sirolimus
  • +3 more
  • Hackensack, New Jersey
    John Theurer Cancer Center at Hackensack University Medical Cent
Feb 4, 2022

Chronic GVHD Trial in Duarte (biological, procedure, other)

Active, not recruiting
  • Chronic Graft Versus Host Disease
  • Aldesleukin
  • +3 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

NSCLC (NSCLC) Trial in Basel (F16IL2, Nivolumab, fixed dose)

Active, not recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Basel, Switzerland
    Basel University Hospital
Jul 19, 2022

Periodontitis, Diabetes, Type 2 Trial in Istanbul (Non-Surgical Periodontal Treatment)

Completed
  • Periodontitis
  • Diabetes Mellitus, Type 2
  • Non-Surgical Periodontal Treatment
  • Istanbul, Turkey
    Marmara University
Nov 11, 2023

Advanced Solid Tumor, Unresectable Solid Tumor, Melanoma Trial in Australia, Canada, United States (MDNA11 Monotherapy, MDNA11

Recruiting
  • Advanced Solid Tumor
  • +24 more
  • MDNA11 Monotherapy
  • MDNA11 in combination with checkpoint inhibitor
  • Santa Monica, California
  • +7 more
Nov 1, 2022

Systemic Lupus Erythematosus Trial in Beijing (Telitacicept, Interleukin-2)

Recruiting
  • Systemic Lupus Erythematosus
  • Beijing, Beijing, China
    Department of Rheumatology and Immunology, Peking University Peo
Apr 26, 2022

Systemic Lupus Erythematosus Trial in Beijing (Belimumab, Interleukin-2)

Recruiting
  • Systemic Lupus Erythematosus
  • Beijing, China
    Department of Rheumatology and Immunology, Peking University Peo
Mar 24, 2022

Metastatic Melanoma Stage IV Trial in Tuebingen, Siena (L19IL2 - Ph I, L19IL2 at RD - Ph II, DTIC)

Active, not recruiting
  • Metastatic Melanoma Stage IV
  • L19IL2 - Ph I
  • +2 more
  • Tuebingen, Germany
  • +1 more
Apr 13, 2022

Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Atlanta (Aldesleukin,

Not yet recruiting
  • Lung Non-Small Cell Carcinoma
  • +3 more
  • Aldesleukin
  • Pembrolizumab
  • Atlanta, Georgia
    Emory University/Winship Cancer Institute
Aug 8, 2022

Diffuse Large B-cell Lymphoma (DLBCL) Trial in Münster (L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab)

Active, not recruiting
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • L19-IL2 - Ph I
  • +2 more
  • Münster, Germany
    Münster University Hospital
Apr 19, 2022

Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Trial in

Not yet recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • +3 more
  • Biospecimen Collection
  • +8 more
  • Kansas City, Kansas
    University of Kansas Cancer Center
Nov 27, 2023

Non Small Cell Lung Cancer, Stage IV NSCLC, Recurrent Non Small Cell Lung Cancer Trial in Tampa (biological, drug, other)

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Tumor-infiltrating Lymphocytes (TIL)
  • +5 more
  • Tampa, Florida
    Moffitt Cancer Center
Dec 28, 2022

Metastatic Melanoma Trial in Portland (Radiation therapy and high-dose IL-2, High-dose IL-2)

Active, not recruiting
  • Metastatic Melanoma
  • Radiation therapy and high-dose IL-2
  • High-dose IL-2
  • Portland, Oregon
    Providence Cancer Center
Sep 23, 2021

Solid Malignancies or Lymphomas Trial in Wollongong (IBI363)

Recruiting
  • Solid Malignancies or Lymphomas
  • IBI363
  • Wollongong, New South Wales, Australia
    Southern Medical Day Care Centre
Sep 4, 2022

Advanced Refractory Solid Tumors Trial in China (Hypofractionated radiotherapy, PD-1 inhibitor, GM-CSF)

Recruiting
  • Advanced Refractory Solid Tumors
  • Hypofractionated radiotherapy
  • +3 more
  • Beijing, China
  • +15 more
Aug 8, 2022

BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Merkel Cell Carcinoma Trial in Marseille (L19IL2/L19TNF)

Not yet recruiting
  • BCC - Basal Cell Carcinoma
  • +6 more
  • Marseille, France
    Hôpital de la Timone
Jun 22, 2022

Advanced Breast Cancer, Advanced Lung Cancer Trial (Tumor-infiltrating lymphocytes, IL-2)

Not yet recruiting
  • Advanced Breast Cancer
  • Advanced Lung Cancer
  • Tumor-infiltrating lymphocytes
  • IL-2
  • (no location specified)
Oct 26, 2023

Bipolar Depression Trial in Créteil (ILT101, Placebos)

Recruiting
  • Bipolar Depression
  • Créteil, Hôpital Albert Chenevier, France
    Pr Marion Leboyer
Dec 10, 2021

Healthy Volunteers Trial in Paris (ILT101, Placebo)

Completed
  • Healthy Volunteers
  • Paris, France
    Clinical Investigation Center Paris Est Hôpital Universitaire Pi
Dec 10, 2021

Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia Trial in Boston (Cytokine-Induced Memory-like Natural Killer

Not yet recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Cytokine-Induced Memory-like Natural Killer Cells
  • +2 more
  • Boston, Massachusetts
  • +1 more
Nov 22, 2023

Multiple Myeloma Trial in Boston (CIML NK Cells plus KP1237 and low dose IL-2)

Recruiting
  • Multiple Myeloma
  • CIML NK Cells plus KP1237 and low dose IL-2
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 18, 2022

Acute Myeloid Leukemia (AML) Relapse Trial in Freiburg, Münster (F16IL2, BI 836858)

Completed
  • Acute Myeloid Leukemia (AML) Relapse
  • Freiburg, Germany
  • +1 more
Apr 13, 2022